Our Company

1 of 1
1-1 of 1
Survival of Medicare fee-for-service chemotherapy patients by site of care07 February 2018 - By Pamela M. Pelizzari and Christine Ferro and Sean Pittinger and Bruce S. Pyenson - Article

This report compares the 36-month cancer survival rate by treatment facility type for 46,762 Medicare fee-for-service patients treated with chemotherapy under the Medicare Part B benefit for breast, colon, lung, ovarian, pancreatic, or prostate cancer.

1 of 1

  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman